Teva Pharmaceutical Industries Limited
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-16.27B | $329.0M | $1.59B | $3.06B | $1.27B | $1.96B | $2.76B | $3.33B |
| Depreciation & Amortization | $2.11B | $1.52B | $1.31B | $1.51B | $1.64B | $1.71B | $1.07B | $977.0M |
| Depreciation | $632.0M | $501.0M | $449.0M | $464.0M | $458.0M | $428.0M | $358.0M | $448.0M |
| Amortization | $1.44B | $993.0M | $838.0M | $1.04B | $1.18B | $1.27B | $707.0M | $527.0M |
| Stock-Based Compensation | $133.0M | $124.0M | $117.0M | $95.0M | $64.0M | $82.0M | $91.0M | $80.0M |
| Net Cash from Operating Activities | $2.23B | $3.89B | $5.54B | $5.13B | $3.24B | $4.57B | $4.13B | $4.14B |
| Investing Activities | ||||||||
| Capital Expenditures | $874.0M | $901.0M | $772.0M | $929.0M | $1.03B | $1.10B | $1.05B | $710.0M |
| Business Acquisitions | $-43.0M | $36.15B | $3.31B | $363.0M | $39.0M | $0 | $6.56B | $4.95B |
| Net Cash from Investing Activities | $3.45B | $-34.41B | $-5.57B | $-1.45B | $-1.15B | $-1.13B | $-7.60B | $-5.46B |
| Financing Activities | ||||||||
| Dividends Paid | $901.0M | $1.30B | $1.16B | $1.16B | $1.09B | $855.0M | $800.0M | $668.0M |
| Stock Repurchases | $0 | $0 | $439.0M | $500.0M | $497.0M | $1.16B | $899.0M | $99.0M |
| Net Cash from Financing Activities | $-5.75B | $25.22B | $4.81B | $-2.38B | $-3.88B | $-1.68B | $3.34B | $573.0M |
| Net Change in Cash | $-25.0M | $-5.96B | $4.72B | $1.19B | $-1.84B | $1.78B | $-152.0M | $-747.0M |
| Free Cash Flow | $1.35B | $2.99B | $4.77B | $4.20B | $2.21B | $3.47B | $3.08B | $3.43B |